SNPMiner Trials (Home Page)
Report for Clinical Trial NCT04042558
 Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene 
      The objective of this study is to assess the efficacy of the combination of Platinum
      (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage
      IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations
      following targeted therapies.
    
NCT04042558  NSCLC Stage IIIB  NSCLC Stage IV  EGFR Gene Mutation  ALK Gene Rearrangement Positive  ROS1 Gene Mutation 
  2  Interventions 
 
Name: Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
Description: 4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles
 Type: Drug
Group Labels:  1  Cohort with Bevacizumab  
 Name: Carboplatin + Pemetrexed + Atezolizumab
Description: Carboplatin + Pemetrexed + Atezolizumab
 Type: Drug
Group Labels:  1  Cohort without Bevacizumab  
  
Primary Outcomes 
 Measure: Objective response rate (ORR) according to RECIST 1.1 Time: After the end of 4 cycles (15 weeks)
   
Secondary Outcomes 
 Measure: The progression-free survival (PFS) Time: 1 year
 Measure: The overall survival Time: 1 year
 Measure: The duration of response Time: 1 year
 
Purpose: Treatment
Allocation: Non-Randomized
Parallel Assignment 
There is one SNP
SNPs
After a first line of treatment with a TKI, most
      patients progress and are eligible according to the mechanism of progression to a TKI of 3rd
      generation in case of T790M resistance or chemotherapy. --- T790M ---